{
  "meta": {
    "data_length": 1,
    "message": "Proposition id prop:vtxr:534 retrieved successfully",
    "request_url": "http://api.moalmanac.org/propositions?proposition_id=prop%3Avtxr%3A534",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.001803,
    "timestamp_received": "2026-09-25T04:54:02.947886+00:00Z",
    "timestamp_returned": "2026-09-25T04:54:02.949689+00:00Z",
    "trace_id": "c296c8b8-f74d-4365-9cea-adf64743b705"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-08-02"
  },
  "data": [
    {
      "id": "prop:vtxr:534",
      "type": "VariantTherapeuticResponseProposition",
      "predicate": "predictsSensitivityTo",
      "subjectVariant": {
        "type": "CategoricalVariant",
        "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition."
      },
      "conditionQualifier": {
        "id": "dis:ncit:C3467",
        "conceptType": "Disease",
        "name": "Cutaneous T-cell Lymphoma",
        "mappings": [],
        "extensions": [
          {
            "name": "solid_tumor",
            "value": false,
            "description": "Boolean value for if this tumor type is categorized as a solid tumor."
          }
        ],
        "primaryCoding": {
          "id": "coding:ncit:C3467",
          "code": "C3467",
          "name": "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",
          "system": "https://evsexplore.semantics.cancer.gov",
          "systemVersion": "25.01d",
          "iris": [
            "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C3467"
          ]
        }
      },
      "objectTherapeutic": {
        "id": "tx:ncit:C66944",
        "conceptType": "Therapy",
        "name": "Brentuximab vedotin",
        "mappings": [
          {
            "relation": "relatedMatch",
            "coding": {
              "id": "coding:rxcui:1147320",
              "code": "1147320",
              "name": "brentuximab vedotin",
              "system": "RxNorm",
              "systemVersion": "20250602",
              "iris": [
                "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1147320"
              ]
            }
          },
          {
            "relation": "relatedMatch",
            "coding": {
              "id": "coding:omop:37017170",
              "code": "37017170",
              "name": "Brentuximab vedotin",
              "system": "OMOP",
              "systemVersion": "v20250827",
              "iris": [
                "https://athena.ohdsi.org/search-terms/terms/37017170"
              ]
            }
          },
          {
            "relation": "relatedMatch",
            "coding": {
              "id": "coding:sctid:713395006",
              "code": "713395006",
              "name": "Brentuximab vedotin",
              "system": "SNOMED",
              "systemVersion": "2025-03-01",
              "iris": [
                "https://browser.ihtsdotools.org/?perspective=full&conceptId1=713395006&edition=MAIN/2025-03-01&release=&languages=en"
              ]
            }
          },
          {
            "relation": "relatedMatch",
            "coding": {
              "id": "coding:omop:40241969",
              "code": "40241969",
              "name": "brentuximab vedotin",
              "system": "OMOP",
              "systemVersion": "v20250827",
              "iris": [
                "https://athena.ohdsi.org/search-terms/terms/40241969"
              ]
            }
          }
        ],
        "extensions": [
          {
            "name": "therapy_strategy",
            "value": [
              "target CD30 antigens"
            ],
            "description": "Associated therapeutic strategy or mechanism of action of the therapy."
          },
          {
            "name": "therapy_type",
            "value": "Targeted therapy",
            "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
          }
        ],
        "primaryCoding": {
          "id": "coding:ncit:C66944",
          "code": "C66944",
          "name": "Brentuximab Vedotin",
          "system": "https://evsexplore.semantics.cancer.gov",
          "systemVersion": "25.01d",
          "iris": [
            "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66944"
          ]
        }
      },
      "extensions": [
        {
          "name": "biomarkers",
          "value": [
            {
              "id": "bmkr.criterion:0",
              "present": true,
              "subject": {
                "id": "bmkr:0",
                "type": "CategoricalVariant",
                "name": "CD30 +",
                "constraints": [],
                "extensions": [
                  {
                    "name": "biomarker_type",
                    "value": "Protein expression"
                  },
                  {
                    "name": "marker",
                    "value": "CD30"
                  },
                  {
                    "name": "unit",
                    "value": "status"
                  },
                  {
                    "name": "equality",
                    "value": "="
                  },
                  {
                    "name": "value",
                    "value": "Positive"
                  }
                ]
              }
            }
          ],
          "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic."
        }
      ]
    }
  ]
}